NCT06545955ClinicalTrials.gov

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.

Contatta questo studio

In breve

Fase 3250 partecipanti ricercati76 centri7 paesi

Categorie

Oncologia74%Nefrologia e urologia26%

Registrato in 1 registro

ClinicalTrials.govNCT06545955Apri questa scheda su ClinicalTrials.govSincronizzato mese scorso

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2024-08-09; recorded start 2024-10-01
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Not stated: Open label (no blinding)Masking is recorded as none (open label)
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 16 other studies in this databaseCounted from the lead sponsor named in the record (Ferring Pharmaceuticals)
Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourMODERATE

A moderately rigorous design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding0/20
Open-label
Control arm0/15
No comparator arm stated in the record
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 76 sites
Data monitoring committee0/7
Data monitoring committee not stated in the record
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 250 participants (target), run at 76 sites, across 7 countries.

How this score is built

Enrolment23/40
250 participants (target)
Site count22/25
76 sites
Country count12/15
7 countries
Planned duration10/10
Planned over about 76 months
Sponsor scale4/10
Ferring Pharmaceuticals has led 17 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy will be evaluated in participants with NMIBC CIS (± high-grade Ta/T1).

Patologie

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Idoneità

Idoneità
Sesso	Tutti
Età	18 Years – Nessun massimo
Volontari sani	No

Idoneità come riportata nel registro

Inclusion Criteria: * Diagnosed, as documented, with carcinoma in situ (CIS) ±Ta/T1 high-grade disease. * For T1 disease biopsies should contain muscle fibres. * Unresponsive to ≥2 courses of Bacillus Calmette-Guerin (BCG) therapy within the last 12 months. BCG-unresponsive refers to participants with high-grade non-muscle invasive bladder cancer (NMIBC) who are unlikely to benefit from and who will not be receiving further intravesical BCG. The term "BCG-Unresponsive" includes participants who did not respond to BCG treatment and have a persistent high-grade recurrence within 12 months after BCG was initiated, and those who despite an initial complete response to BCG, relapse with CIS within 12 months of their last intravesical treatment with BCG or relapse with high-grade Ta/T1 NMIBC within 6 months of their last intravesical treatment with BCG. The following criteria define the participants who may be included in the trial: * Have received at least 2 courses of BCG within a 12 month period - defined as at least 5 of 6 induction BCG instillations and at least 2 of 3 instillations of maintenance BCG, or at least 2 of 6 instillations of a second induction course, where maintenance BCG is not given. o Exception: those who have T1 high-grade disease at 1st evaluation after induction BCG alone (at least 5 of 6 doses) may qualify in the absence of disease progression * At the time of tumour recurrence, participants with CIS alone or high-grade Ta/T1 with CIS should be within 12 months of last exposure to BCG * No maximum limit to the amount of BCG administered * All visible papillary tumours must be resected and those with persistent T1 disease on transurethral resection of bladder tumour (TURBT) should undergo an additional re-TURBT within 14 to 70 days prior to beginning trial treatment. Obvious areas of CIS should also be fulgurated * Eastern Cooperative Oncology Group (ECOG) status ≤2 * Aged ≥18 years at the time of consent * Available for the whole duration of the trial * Life expectancy \>2 years, in the opinion of the investigator * Absence of concomitant upper tract urothelial carcinoma or urothelial carcinoma within the prostatic urethra. Freedom from upper tract disease (if clinically indicated) as indicated by no evidence of upper tract tumour by either intravenous pyelogram, retrograde pyelogram, computed tomography (CT) scan with or without urogram, or magnetic resonance imaging (MRI) with or without urogram performed within 6 months of enrolment. Absence of locally advanced disease as assessed by CT scan or MRI * Participants who elect not to undergo cystectomy * Participants with prostate cancer on active surveillance at low risk for progression are permitted to be included into the trial at the discretion of the investigator * Females of reproductive potential must have a negative highly sensitive urine or serum pregnancy test upon entry into this trial and be willing to use highly effective contraception during treatment with the investigational medicinal product and for 6 months following the last dose. Otherwise, female participants must be post-menopausal (no menstrual period for a minimum of 12 months, as confirmed by follicle-stimulating hormone levels) or surgically sterile * Male subjects must be willing to use a male condom and effective contraception during sex throughout the treatment period and for 3 months following the last dose. Exclusion Criteria: * Current or previous evidence of muscle-invasive (muscularis propria) or metastatic disease presented at the screening visit. Examples of increased risk of muscle-invasive disease include but are not limited to: * Presence of lymphovascular invasion and / or micropapillary, sarcomatoid, plasmacytoid and / or neuroendocrine disease as shown in the histology of the biopsy sample * Participants with CIS+T1 disease accompanied by the presence of hydronephrosis secondary to the primary tumour * Current systemic therapy for bladder cancer other than investigational medicinal products used in randomisation arm * Current or prior investigational treatment for BCG-unresponsive NMIBC or any other investigational drug (drug used in a clinical trial, i.e drug used in a Ferring sponsored non interventional study does not apply) within 1 month prior to screening * Current or prior pelvic external beam radiotherapy within 2 years of screening * Prior treatment with nadofaragene firadenovec at any time * Prior systemic therapy for bladder cancer at any time * Prior intravesical chemotherapy for the treatment of BCG-unresponsive NMIBC

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studio	Interventistico
Fase	Fase 3
Assegnazione	Randomizzata
Modello di intervento	PARALLEL
Finalità principale	TREATMENT
Mascheramento	NONE (0)
Arruolamento	250 partecipanti ricercati

Sponsor e collaboratori

Ferring Pharmaceuticals Sponsor

Bracci e interventi

Nadofaragene firadenovecEXPERIMENTAL
Nadofaragene firadenovec (intravesical)
Nadofaragene firadenovec + gemcitabine & docetaxelEXPERIMENTAL
Nadofaragene firadenovec (intravesical), and sequential gemcitabine and docetaxel (intravesical)
Nadofaragene firadenovec + PembrolizumabEXPERIMENTAL
Nadofaragene firadenovec (intravesical), and pembrolizumab (IV infusion). This arm will be closed and patients will no longer be randomised to this arm. This modification will convert ABLE-22 into a two-arm study with 1:1 randomisation between nadofaragene alone and nadofaragene + gemcitabine/docetaxel, to now N=100 in each of the 2 remaining arms. Participants already enrolled in this arm will not be impacted.

Interventi

Farmaco Docetaxel
Intravesical Docetaxel chemotherapy, used in combination with Gemcitabine.
Farmaco Gemcitabine
Intravesical Gemcitabine chemotherapy, used in combination with Docetaxel.
Farmaco Nadofaragene Firadenovec
vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
Farmaco Pembrolizumab
Pembrolizumab is an FDA approved immune checkpoint inhibitor which restores the anti-tumour immune response by blocking the programmed cell death protein 1 (PD-1). Pembrolizumab is administered via intravenous (IV) infusion.

Esiti misurati

Esito primario
Complete response
Complete response (CR) at any time from first treatment (defined as absence of high-grade (HG) recurrence).
Orizzonte temporale up to 6 months
Esito secondario
Complete response at month 6
Complete response 6 months from first treatment
Orizzonte temporale 6 months
Esito secondario
Complete response at month 3
Complete response 3 months from first treatment
Orizzonte temporale 3 months
Esito secondario
Durability of complete response
Durability of complete response (defined as time from achieved CR to HG recurrence, progression or death due to any cause).
Orizzonte temporale Up to 24 months
Esito secondario
Muscle-invasive progression of disease
Muscle-invasive progression of disease (defined as time from first treatment to first evidence of muscle-invasive disease or death)
Orizzonte temporale up to 36 months
Esito secondario
Cystectomy-free survival
Cystectomy-free survival (defined as time from first treatment to either cystectomy or death due to any cause)
Orizzonte temporale up to 36 months
Esito secondario
Pathological staging
Pathological staging (tumor, node, metastasis staging system) in participants at time of cystectomy
Orizzonte temporale up to 36 months
Esito secondario
Overall survival
Overall survival (defined as time from first treatment to death due to any cause)
Orizzonte temporale up to 36 months
Esito secondario
Evidence of malignant lesions of the upper tract and/or prostatic urethra
Evidence of malignant lesions of the upper tract and/or prostatic urethra (defined as time from first treatment to first evidence of malignant lesions).
Orizzonte temporale up to 24 months
Esito secondario
Adverse events
Adverse events collected for nadofaragene firadenovec in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab)
Orizzonte temporale up to 36 months

Date

Date
Data di inizio	1 ottobre 2024 (effettiva)
Conclusione primaria	30 giugno 2028 (stimata)
Conclusione	31 dicembre 2030 (stimata)
Prima pubblicazione	9 agosto 2024 (effettiva)
Ultimo aggiornamento	6 agosto 2026
Risultati pubblicati	Non indicato nella scheda del registro
Stato verificato l'ultima volta	novembre 2025

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

76 centri stanno reclutando

Canada

Canada
Struttura	Città	Stato o regione	Stato
Prostate Cancer Centre	Calgary	Alberta	In reclutamento
Centre Hospitalier de L'Universite de Montreal	Montreal	Quebec	In reclutamento
University Health Network UHN - Princess Margaret Cancer Centre	Toronto	Ontario	In reclutamento

Czechia

Czechia
Struttura	Città	Stato o regione	Stato
Kromerizska Nemocnice A S	Kroměříž	Zlín	In reclutamento
Krajska Nemocnice Liberec	Liberec	Liberec Region	In reclutamento
Fakultní Thomayerova Nemocnice	Prague	Prague	In reclutamento
Fakultni nemocnice v Motole	Prague	Prague	In reclutamento
Androgeos, spol. s r.o.	Prague	Prague	In reclutamento

France

France
Struttura	Città	Stato o regione	Stato
CHU de Bordeaux - Hôpital Pellegrin	Bordeaux	New Aquitaine	In reclutamento
CHU Clermont Ferrand - Hopital Gabriel Montpied	Clermont-Ferrand	Auvergne-Rhône-Alpes	In reclutamento
Centre Hospitaliser Universitaire de Lyon Sud	Lyon	Rhone.Alpe	In reclutamento
Hospices Civils de Lyon - Edouard Herriot Hosp.	Lyon	Auvergne-Rhône-Alpes	In reclutamento
CHU Nantes - Hotel Dieu	Nantes	Nantes	In reclutamento
Centre Hospitalier Universitaire De Nimes (Nîmes)	Nîmes	Occitanie	In reclutamento
Hopital La Pitie Salpetriere	Paris		In reclutamento
APHP - Hopital Bichat	Paris	Île-de-France Region	In reclutamento
CHU Toulouse - Hopital Rangueil	Toulouse	Huate-Garonne	In reclutamento

Poland

Poland
Struttura	Città	Stato o regione	Stato
IN-VIVO Bydgoszcz	Bydgoszcz	Kuyavian-Pomeranian Voivodeship	In reclutamento
Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k.	Poznan	Wielkopolska	In reclutamento
Medical Concierge Centrum Medyczne	Warsaw	Woj. Mazowieckie	In reclutamento

South Korea

South Korea
Struttura	Città	Stato o regione	Stato
Seoul National University Hospital	Seoul	Songpa-gu	In reclutamento
Samsung Medical Center	Seoul	Seoul	In reclutamento
Korea University Anam Hospital	Seoul	Seoul	In reclutamento
Pusan National University Yangsan Hospital	Yangsan	Gyeongsangnam-do	In reclutamento

Spain

Spain
Struttura	Città	Stato o regione	Stato
Hospital Universitario de A Coruna	A Coruña	Galicia	In reclutamento
Hospital Universitario Fundacion Alcorcon	Alcorcón	Madrid	In reclutamento
Hospital del Mar	Barcelona	Catalonia	In reclutamento
Hospital Clinic De Barcelona - University of Barcelona	Barcelona	Catalonia	In reclutamento
Hospital Universitario Basurto	Bilbao	Vizcaya	In reclutamento
Hospital Universitario Reina Sofia	Córdoba	Cordoba	In reclutamento
Clinica Universidad de Navarra - Madrid	Madrid	Madrid	In reclutamento
MD Anderson Cancer Center	Madrid		In reclutamento
Hospital Universitario 12 De Octubre (Madrid)	Madrid	Madrid	In reclutamento
Universidad Autonoma de Madrid. Hospital Universitario La Paz	Madrid	Madrid	In reclutamento
Servicio Andaluz de Salud (SAS) - Hospital Universitario Virgen de la Victoria (HUVV)	Málaga		In reclutamento
Clinica Universidad de Navarra - Pamplona	Pamplona	Navarre	In reclutamento
Instituto de Investigacion Valdecilla (IDIVAL) / Hospital universitario Marques de Valdecilla	Santander	Cantabria	In reclutamento

United States

United States
Struttura	Città	Stato o regione	Stato
Anne Arundel Urology, PA	Annapolis	Maryland	In reclutamento
Emory University	Atlanta	Georgia	In reclutamento
Georgia Urology	Atlanta	Georgia	In reclutamento
Urology Austin	Austin	Texas	In reclutamento
MidLantic Urology	Bala-Cynwyd	Pennsylvania	In reclutamento
Boise VA Medical Center	Boise	Idaho	In reclutamento
Roswell Park Cancer Institute	Buffalo	New York	In reclutamento
Great Lakes Physician PC d/b/a Western new York Urology Associates	Cheektowaga	New York	In reclutamento
University of Cincinnati	Cincinnati	Ohio	In reclutamento
OSU Arthur James Cancer Hospital	Columbus	Ohio	In reclutamento
Urology Clinics of North Texas PLLC (Dallas)	Dallas	Texas	In reclutamento
University of Texas Southwestern Medical Center - Urology Clinic	Dallas	Texas	In reclutamento
Advent Health	Denver	Colorado	In reclutamento

Nella scheda del registro sono indicati altri 26 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

Non è stata registrata alcuna modifica da quando abbiamo acquisito questa scheda.

Viene registrata una modifica ogni volta che lo sponsor aggiorna la scheda del registro. Stato, date, arruolamento e centri compaiono qui man mano che cambiano.

Registro: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT06545955